Renaissance Technologies
TSHA icon

Renaissance Technologies’s Taysha Gene Therapies TSHA Stock Holding History

Renaissance Technologies’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Buy
413,203
+242,103
+141% +$1.13M ﹤0.01% 1943
2025
Q4 		$941K Buy
+171,100
New +$831K ﹤0.01% 2318
2025
Q3 		– Sell
-54,900
Closed -$127K – 3934
2025
Q2 		$127K Buy
+54,900
New +$119K ﹤0.01% 3262
2025
Q1 		– Sell
-878,448
Closed -$1.52M – 3846
2024
Q4 		$1.52M Buy
+878,448
New +$1.82M ﹤0.01% 2226
2024
Q3 		– Sell
-41,100
Closed -$92.1K – 3899
2024
Q2 		$92.1K Sell
41,100
-287,400
-87% -$836K ﹤0.01% 3198
2024
Q1 		$943K Sell
328,500
-768,900
-70% -$1.6M ﹤0.01% 2525
2023
Q4 		$1.94M Buy
1,097,400
+499,400
+84% +$996K ﹤0.01% 1962
2023
Q3 		$1.89M Buy
598,000
+373,600
+166% +$698K ﹤0.01% 1903
2023
Q2 		$148K Sell
224,400
-25,200
-10% -$18.2K ﹤0.01% 3363
2023
Q1 		$199K Sell
249,600
-270,200
-52% -$349K ﹤0.01% 3288
2022
Q4 		$1.18M Buy
519,800
+101,300
+24% +$205K ﹤0.01% 2435
2022
Q3 		$808K Sell
418,500
-105,100
-20% -$382K ﹤0.01% 2627
2022
Q2 		$1.95M Buy
523,600
+273,100
+109% +$1.08M ﹤0.01% 2212
2022
Q1 		$1.63M Buy
+250,500
New +$1.87M ﹤0.01% 2381

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies's TSHA Position: Q1 2026 in Review

Renaissance Technologies increased its Taysha Gene Therapies (TSHA) stake by 141% in Q1 2026, buying an estimated $1.13M and bringing the position to 413,203 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Renaissance Technologies first reported a position in TSHA in Q1 2022 and has held it in 14 quarters since. The position peaked at $1.95M in Q2 2022. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Renaissance Technologies held 413,203 shares of Taysha Gene Therapies worth $1.85M as of Q1 2026.
  • Renaissance Technologies bought 242,103 Taysha Gene Therapies shares in Q1 2026, an estimated $1.13M.
  • Taysha Gene Therapies made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1943 holding.
  • Renaissance Technologies first reported a position in Taysha Gene Therapies in Q1 2022 and has held it in 14 quarters since.
  • Renaissance Technologies's Taysha Gene Therapies position peaked at $1.95M in Q2 2022.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.